Skip to content

CAIman 5 Articulating Maryland in coloRECTAL Cancer Surgery

CAIman 5 Articulating Maryland in coloRECTAL Cancer Surgery. An Observational, Prospective, Post-marketing Clinical Follow-up Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04175756
Acronym
CAIRECTAL
Enrollment
61
Registered
2019-11-25
Start date
2020-01-02
Completion date
2021-04-28
Last updated
2021-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

colorectal cancer, laparoscopic surgery, Seal & Cut, Total Mesorectal Excision (TME), Partial Mesorectal Excision (PME), Complete Mesocolic Excision (CME)

Brief summary

This voluntary study is part of a Post-Market-Surveillance plan to proactively collect clinical data for the use of Caiman 5 articulating Maryland in colorectal surgery under daily clinical routine.

Interventions

DEVICECaiman 5 articulating Maryland

Laparoscopic colorectal surgery

Sponsors

Aesculap AG
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient´s written informed consent * Planned laparoscopic colorectal cancer surgery using Caiman 5 articulating Maryland (according to the IfU) * Age ≥18 years

Exclusion criteria

* Emergency surgery * Pregnancy * Participation in another surgical study, which might influence the intraoperative process * Conversion to open surgery * Conversion to another sealing / cutting instrument (instead of Caiman 5 articulating Maryland)

Design outcomes

Primary

MeasureTime frameDescription
Total operative timeintraoperativelyTime between first incision and closure of the surgical incision

Secondary

MeasureTime frameDescription
Handling characteristicsintraoperativeEvaluation of performance and handling characteristics using a questionnaire containing 5-level Likert scales (excellent, very good, good, fair, poor)
Estimated intraoperative blood lossintraoperativeintraoperative blood loss in ml
Time needed for TMEIntraoperativeTime between end of left flexure mobilization and stapling
Time needed for PMEIntraoperativeTime \[in minutes\] between end of left flexure mobilization and stapling
Time needed for CMEIntraoperativeTime \[in minutes\] between end of ileocolic vessels clipping and start of right flexure mobilization
Time needed for right / hepatic colic flexure mobilizationIntraoperativeTime \[in minutes\] between end CME and start of resection of the mesentery of the small intestine
Complicationsup to 4 months postoperativeNumber of Complications: Wound infections, Urinary tract infections, Pulmonary infections, Other infections, Wound dehiscence, Anastomotic leak, Anastomotic bleeding, Other bleeding / hemorrhage, Intraabdominal abscess, Fistula, Peritonitis, Sepsis, Hernia, Stenosis Ileus, Ureter injury, Nerve injury, Cardiac complications, Other
Stay in intensive care unit postopup to discharge (approximately 10 days postoperative)Number of days postoperative until discharge from intensive care unit
Stay in intermediate care unit stay postopup to discharge (approximately 10 days postoperative)Number of days postoperative until discharge from intermediate care unit stay
First postoperative oral intakeup to discharge (approximately 10 days postoperative)Number of days until patient's first postoperative oral intake
First postoperative stoolup to discharge (approximately 10 days postoperative)Number of days until patient's first postoperative stool after oral intake
Quality of excision: M.E.R.C.U.R.Y. criteriaup to discharge (approximately 10 days postoperative)quality of mesorectal excision according to criteria established in the Magnetic Resonance Imaging and Rectal Cancer European Equivalence Study (M.E.R.C.U.R.Y.)
Time needed for left / splenic colic flexure mobilizationIntraoperativeTime \[in minutes\] between clipping of inferior mesenteric vessels and start of TME, PME or corresponding)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026